title: Topical difluprednate monotherapy for uveitic macular edema.
abstract: OBJECTIVE
  To describe the use of topical difluprednate for the treatment of uveitic macular edema.
  
  
  METHODS
  Retrospective review of 3 consecutive cases of uveitic macular edema.
  
  
  METHODS
  Patients were treated with topical difluprednate monotherapy.
  
  
  RESULTS
  All patients experienced complete resolution of uveitic macular edema within 2-4 weeks. We observed a statistically significant improvement in central subfield macular thickness (p = 0.04). There was an overall improvement in visual acuity, but this result was not statistically significant (p = 0.33).
  
  
  CONCLUSIONS
  Topical difluprednate can be effective for uveitic macular edema. Further investigation of this therapy in prospective randomized controlled trials is warranted.
authors.affiliation: Department of Ophthalmology, University of British Columbia, Vancouver, BC.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Symes
authors.affiliation: Department of Ophthalmology, University of British Columbia, Vancouver, BC. Electronic address: farzin.forooghian@gmail.com.
authors.forename: Farzin
authors.initials: F
authors.lastname: Forooghian
mesh_terms: D000287:Administration, Topical; D000328:Adult; D005260:Female; D005477:Fluprednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D009883:Ophthalmic Solutions; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014606:Uveitis, Anterior / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D015867:Uveitis, Intermediate / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D005477:Fluprednisolone; C015808:difluprednate